Brief: Amneal Announces Positive Interim Phase 4 Elevate-Pd Results With Crexont For Parkinson’S Disease
05/12/2025 13:01
Dec 5 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES POSITIVE INTERIM PHASE 4 ELEVATE-PD RESULTS WITH CREXONT® FOR PARKINSON’S DISEASE AMNEAL PHARMA - 55 PATIENTS SHOW SUBSTANTIAL BENEFIT WITH CREXONT AMNEAL PHARMA: ELEVATE-PD STUDY IS ONGOING WITH LONGER-TERM DATA EXPECTED IN 2026 Source text: ID:nGNX4J5Bsp Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study